Under the Spotlight AUS: BrainChip (BRN)

3 min read
UTS_BRN_BlogHeader_1440x956-1024x680.webp

AI is the future, but hardware gaps must be closed before it can reach its full potential. An ASX-listed company is on the case, with a brain-mimicking processor designed for better machine learning. Today we put BrainChip Under the Spotlight.

UTS-Fact-File_DARK-1.webp

The World Economic Forum (WEF) has named Artificial Intelligence (AI) a key driver of the Fourth Industrial Revolution, impacting everything from energy efficiency to elder care within Gen Z’s lifetime. But the technology has several obstacles to overcome before it’s ready for true mass adoption.

ASX-listed company BrainChip Holdings ($BRN) is doing its part. Co-founder and Chief Technology Officer (CTO) Peter Van Der Made first patented the Akida chip in 2008. By early 2022, the technology had reached the point where the Akida chip was ready to go to market.

Low power, high speed

The Akida technology is based on a unique form of neuromorphic processor – ‘neuro’ relating to nerves or the nervous system, and ‘morphic’ meaning ‘taking the shape of’. A neuromorphic processor is inspired by the human brain by enabling the interpretation of sensory data without programming.

The IP behind the Akida chip creates a set of specific neural pathways that facilitates a higher quality of machine learning (ML), and ‘processes data with unparalleled efficiency, precision, and economy of energy’, according to BrainChip. ‘Keeping AI/ML local to the chip and independent of the cloud dramatically reduces latency while improving privacy and data security’.

BrainChip’s design is ahead of the pack, and management is excited about its commercial prospects.

UTS_BRN_Blog1_1200x600.webp

Time to commercialise

The company has two avenues for generating revenue from Akida. The first is to sell the chips directly to end users, such as the defence and healthcare industries. During H1 2022, BrainChip sold US$218,575 worth of chips.

The second is to licence Akida’s design to another party, like MegaChips, for a fee. BrainChip generated US$4.1m in licence revenue in H1 2022.

Despite the 500% increase in revenue year-on-year, BrainChip generated an US$8.3m loss during H1 2022. But investors need not worry about these losses just yet, as the reporting period’s ending cash allowed for approximately 1.8 years of costs before additional shareholder dilution would be required.

UTS_BRN_Blog3_1200x600.webp

Make or break

We don’t live in a rational world, and superior technology has lost plenty of fights for industry adoption in the past. BrainChip seems aware of this danger. During the annual general meeting (AGM), Chairman Antonio Viana said:

‘VHS vs BetaMax… This is a lesson in how the “best” technology sometimes doesn’t win. BetaMax was smaller, cheaper, equivalent in quality (if not better) to VHS, and its machines were smaller and easier to manufacture. Well, VHS won over all the film production companies by signing exclusive deals. This in essence captured the market.’

In the AI race, there are few spots for semiconductor chips. With all the money spent on developing Akida’s technology, failure for it to be adopted by the industry would likely mean bankruptcy for BrainChip. While this adoption risk remains, investors should be pleased that at least the technological development risk has diminished.

This does not constitute financial advice nor a recommendation to invest in the securities listed. The information presented is intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing.


Subscribe

By subscribing, you agree to our Privacy Policy.

Footer


Made in Australia

Sydney, Australia


Get the app

Scan QR code to download the app

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services Guide, Terms & Conditions, Privacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

This information is being provided in connection with the Australian retail offer component of the initial public offering of shares of Class A common stock (“Shares”) in Anthropic, PBC (“Anthropic”) (“IPO”). The Australian retail offer is an offer of newly issued Shares by Anthropic (“Australian Retail Offer”) made under the Australian prospectus lodged with the Australian Securities and Investments Commission on 11 November 2026 (“Australian Prospectus”). This information does not form part of the Australian Prospectus, and anyone considering applying for Shares under the Australian Retail Offer should rely only on information in the Australian Prospectus and any supplementary or replacement Australian Prospectus. A copy of the Australian Prospectus is available on ipo.anthropic.com. Further information about Anthropic, the IPO, the Shares and the risks of investing in Anthropic is set out in the Australian Prospectus. Anyone considering applying for Shares under the Australian Retail Offer should read and consider the Australian Prospectus in full in deciding whether to acquire Shares under the Australian Retail Offer. Anyone who wants to acquire Shares under the Australian Retail Offer will need to complete the application form that accompanies the Australian Prospectus, in accordance with the process set out in the Australian Prospectus and any other instructions from their broker. Anthropic has applied to list its Class A common stock on the Nasdaq Global Select Market under the symbol “ANT”. Anthropic will not be applying for listing on the Australian Securities Exchange.

Us securities law disclaimer

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to its acceptance after the effective date. The prospectus in the registration statement and other documents Anthropic has filed with the SEC include additional information about Anthropic and the offering. Investors may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. The registration statement (including the US prospectus) is available at www.sec.gov

Copyright © 2026 Stake. All rights reserved.